Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom

AIMS: Midostaurin (MIDO) has been proposed for the treatment of newly-diagnosed adult patients with FMS-like tyrosine kinase 3 mutation-positive (FLT3+) acute myeloid leukemia (AML) in combination with standard chemotherapy. The cost-effectiveness of MIDO and standard of care (SOC) followed by MIDO...

Descripción completa

Detalles Bibliográficos
Autores principales: Tremblay, Gabriel, Dolph, Mike, Patel, Sachin, Brandt, Patricia, Forsythe, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172753/
https://www.ncbi.nlm.nih.gov/pubmed/30323718
http://dx.doi.org/10.1186/s12962-018-0153-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172753/
https://www.ncbi.nlm.nih.gov/pubmed/30323718
http://dx.doi.org/10.1186/s12962-018-0153-4

Ejemplares similares